for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Global Blood Therapeutics Inc

GBT.O

Latest Trade

57.19USD

Change

1.94(+3.51%)

Volume

418,100

Today's Range

54.63

 - 

57.22

52 Week Range

30.15

 - 

64.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
55.25
Open
55.00
Volume
418,100
3M AVG Volume
16.62
Today's High
57.22
Today's Low
54.63
52 Week High
64.94
52 Week Low
30.15
Shares Out (MIL)
60.23
Market Cap (MIL)
3,126.01
Forward P/E
-12.31
Dividend (Yield %)
--

Next Event

Global Blood Therapeutics Inc at Evercore HealthCONx Conference

Latest Developments

More

Global Blood Therapeutics Posts Q3 Loss Per Share $1.07

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor

GBT Says U.S. Food And Drug Administration Accepts New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Global Blood Therapeutics Inc

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Industry

Biotechnology & Drugs

Contact Info

171 Oyster Point Blvd Ste 300

+1.650.7417700

http://www.globalbloodtx.com/

Executive Leadership

Ted Wendell Love

President, Chief Executive Officer, Director

Jeffrey S. Farrow

Chief Financial Officer

Peter Radovich

Senior Vice President, Operations

Jung E. Choi

Chief Business and Strategy Officer

David Louis Johnson

Chief Commercial Officer

Key Stats

1.81 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.480

2017

-2.760

2018

-3.410

2019(E)

-4.215
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.62
Return on Equity (TTM)
-35.55

Latest News

Latest News

BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis

* GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK

BRIEF-Global Blood Therapeutics Announces Proposed Public Offering

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-GBT Appoints David Johnson As Chief Commercial Officer

* GBT APPOINTS INDUSTRY LEADER DAVID L. JOHNSON AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Q4 Loss Per Share $0.94

* GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease

* GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD) Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics posts Q3 loss per share $0.66

* Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results

BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440

* Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440

BRIEF-Global Blood Therapeutics announces discontinuation of IPF program

* Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program

BRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics

* Point72 Asset Management LP reports 5.2 percent passive stake in Global Blood Therapeutics Inc as of October 2 - SEC filing Source text: (http://bit.ly/2yH9e9Y) Further company coverage:

BRIEF-Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease

* Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

BRIEF-Global Blood Therapeutics Q2 loss per share $0.55

* Global Blood Therapeutics reports recent business progress and provides second quarter 2017 financial results

BRIEF-Global Blood Therapeutics expands ongoing Phase 2A hope-kids 1 study into younger pediatric population

* Global Blood Therapeutics expands ongoing phase 2A hope-kids 1 study into younger pediatric population

BRIEF-Global Blood Therapeutics receives EMA PRIME designation for GBT440

* Global blood therapeutics receives ema prime designation for gbt440 for the treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up